Sign in
CompletedPhase 3

Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza A

Key facts

Who runs it
Guangdong Raynovent Biotech Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
157 people enrolled
Started
8 Nov 2025
Ended
25 Jan 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ZSP1273
  • Placebo
Record updated
9 November 2026

Who can take part

Age
12 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Participants and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately
  • Male or female participants aged ≥ 2 to ≤11 years at the time of signing the informed consent form
  • Participants with a diagnosis of influenza virus infection confirmed by all of the following:; Positive rapid antigen test (RAT) for influenza with nasal or throat swabs; The time interval between the onset of symptoms and enrollment is 48 hours or less; Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present

Who cannot take part

  • Participants with any medical history in gastrointestinal that interferes with the absorption of drugs;
  • Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus [HIV] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment;
  • Have received any other investigational products within 3 months prior to dosing;
  • Participants with concurrent infections requiring antimicrobial therapy;
  • Participants with severe influenza virus infection;
  • Positive urine pregnancy test;
  • Participants who are considered inappropriate for the study by the investigator

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial is conducted in China. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ZSP1273 in the treatment of Acute Uncomplicated influenza A in adolescents.

The 2 groups in the trial

  • ZSP1273Treatment being tested
  • PlaceboPlacebo, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind Phase III Clinical Study of ZSP1273 Tablets Compared With Placebo in Children 12-17 Years Old With Acute Uncomplicated Influenza A
Record updated
9 November 2026